Sartorius acquired U.S.–based purification specialist WaterSep BioSeparations through its subgroup Sartorius Stedim Biotech. WaterSep BioSeparations develops, manufactures, and markets hollow-fiber membrane devices and pre-sterilized assemblies for upstream and downstream biopharmaceutical applications.
The privately-owned company based in Marlborough, MA, employs around 15 people and is expected to earn revenue of approximately $2.5 million in 2020. The parties agreed on a purchase price of approximately $27 million, plus an earn-out component of up to $9 million, depending on the achievement of defined sales revenue growth by 2023.
“This acquisition nicely complements our current offering for cell and gene therapy applications, cell harvesting, and various solutions for intensified bioprocessing,” said René Fáber, PhD, head of the Sartorius Bioprocess Solutions Division and executive board member.